1Chaft JE,Oxnard GR,Sima CS. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to Erlotinib or Gefitinib:Implications for clinical trial design[J].Clinical Cancer Research,2011,(19):6298-6303.
2Nishie K,Kawaguchi T,Tamiya A. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease:A retrospective analysis for Japanese patients with activating EGFR mutations[J].JOURNAL OF THORACIC ONCOLOGY,2012,(11):1722-1727.
3Oxnard GR,Lo P,Jackman DM. Delay of chemotherapy through use of post-progression Erlotinib in patients with EGFR-mutant lung cancer[J].Journal of Clinical Oncology,2012,(15suppl):abstr7547.
4Sarah BG,Geoffrey RO,Subba D. Chemotherapy with Erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI)[J].Journal of Clinical Oncology,2012,(15suppl):abstr7524.
